Advanced Synthesis and Catalysis p. 4115 - 4131 (2018)
Update date:2022-08-03
Topics:
Zorn, Katja
Oroz-Guinea, Isabel
Brundiek, Henrike
D?rr, Mark
Bornscheuer, Uwe T.
Biotechnological strategies using renewable materials as starting substrates are a promising alternative to traditional oleochemical processes for the isolation of different fatty acids. Among them, long chain mono-unsaturated fatty acids are especially interesting in industrial lipid modification, since they are precursors of several economically relevant products, including detergents, plastics and lubricants. Therefore, the aim of this study was to develop an enzymatic method in order to increase the percentage of long chain mono-unsaturated fatty acids from Camelina and Crambe oil ethyl ester derivatives, by using selective lipases. Specifically, the focus was on the enrichment of gondoic (C20:1 cisΔ11) and erucic acid (C22:1 cisΔ13) from Camelina and Crambe oil derivatives, respectively. The pursuit of this goal entailed several steps, including: (i) the choice of a suitable lipase scaffold to serve as a protein engineering template (Candida antarctica lipase A); (ii) the identification of potential amino acid targets to disrupt the binding tunnel at the adequate location; (iii) the design, creation and high-throughput screening of lipase mutant libraries; (iv) the study of the selectivity towards different chain length p-nitrophenyl fatty acid esters of the best hits found, as well as the analysis of the contribution of each amino acid change and the outcome of combining several of the aforementioned residue alterations and, finally, (v) the selection and application of the most promising candidates for the fatty acid enrichment biocatalysis. As a result, enrichment of C22:1 from Crambe ethyl esters was achieved either, in the free fatty acid fraction (wt, 78%) or in the esterified fraction (variants V1, 77%; V9, 78% and V19, 74%). Concerning the enrichment of C20:1 when Camelina oil ethyl esters were used as substrate, the best variant was the single mutant V290W, which doubled its content in the esterified fraction from approximately 15% to 34%. A moderately lower increase was achieved by V9 and its two derived triple mutant variants V19 and V20 (27%). (Figure presented.).
View MoreContact:86-512-69362780,69362785
Address:No.69 Weixin Road,Weiting Town,Suzhou Industrial Park
XI'AN CHUKANG BIOTECHNOLOGY CO.,LTD
Contact:29-63685658 63685359
Address:Room 3-1202,Building 1,Oriental oasis,East of Xianning Road,Xi'an,Shaanxi 710043 P.R.China
Jiangsu Zenji Pharmaceuticals LTD
Contact:+86-025-83172562; +1-224-888-1133(USA)
Address:No.5 Xinmofan Road
SHANGHAI ARCADIA BIOTECHNOLOGY LTD.
Contact:+86-21-61353236
Address:SUITE 901, BUILDING WENSLI, 1378 LU JIA BANG RD, SHANGAHI 200011, P.R.CHINA
Jiacheng-Chem Enterprises Limited(expird)
Contact:86-571-86711508
Address:19 Floor, CIBC Holley International Building, No. 198,Wuxing Road, Hangzhou, China,310020
Doi:10.1246/cl.1987.1403
(1987)Doi:10.1023/A:1015521918395
(2002)Doi:10.1021/jm900255t
(2009)Doi:10.1007/BF02886269
(1957)Doi:10.1246/bcsj.62.3024
(1989)Doi:10.1021/ja00222a024
(1988)